Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis

Abstract

Objectives: Biochemical markers reflecting the degradation of the type II collagen helical (Helix-II) and type II collagen C telopeptides (CTX-II) have been developed. Aim: To investigate the association of rapidly destructive hip osteoarthritis with urinary Helix-II and urinary CTX-II. Patients and methods: 12 patients (mean age 70 years) meeting the criteria for rapidly destructive hip osteoarthritis and 28 patients with slowly progressive hip osteoarthritis (mean age 63 years) defined as ,0.20 mm joint space loss/year were included in a case-control study. In each patient, urinary Helix-II and CTX-II were measured at the end of the follow-up period, with retrospective evaluation of x rays. Results: Helix-II levels were 41% (p = 0.002) higher in the 40 patients with hip osteoarthritis than in 75 healthy controls. Increased Helix-II levels were associated with decreased minimum joint space width of the hip (r = 20.57, p = 0.001). Mean urinary Helix-II levels were 71% higher in rapidly destructive than in slowly progressive disease (mean (standard deviation (SD)) ng/mmol Cr: 396 (160) v 232 (118) ng/ mmol; p = 0.002). When levels of Helix-II and CTX-II in the highest tertile were both included in a multivariate logistic regression model, high Helix-II level (OR; (95% CI) 5.73 (1.01 to 32.8)) after adjustment for age and body mass index and high CTX-II level (6.67 (1.14 to 39.0)) were, independently of each other, associated with a rapidly destructive disease. Conclusion: Increased urinary Helix-II levels are associated with rapidly destructive hip osteoarthritis, independently of urinary CTX-II. Measurement of Helix-II, alone or in combination with CTX-II, could be useful for the clinical investigation of patients with hip osteoarthritis.

The chemical biomarkers C2C, Coll2‐1, and Coll2‐1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice

“…In any event, the independent behavior of C2C and Coll2-1 expression suggests that these 2 biomarkers 3344 AMEYE ET AL could both be examined in clinical investigations of OA, as has recently been done for the 622-632 peptide derived from the ␣1 chain of human type II collagen (HELIX-II) and C-terminal crosslinking telopeptide of type II collagen (CTX-II) (29). A small case study showed that, independently of each other, HELIX-II and CTX-II levels are associated with rapidly destructive hip OA and that measurement of both molecules improves diagnosis and the monitoring of disease progression in patients.…”

“…However, the limited availability of biologic samples and the high cost of analysis restrict the number of biomarkers included in individual studies. Since collagen degradation is an important feature of OA, many studies include at least 1 biomarker of type II collagen catabolism, but few (19,29) include multiple markers of this process. Instead, simultaneous monitoring of other biologic processes, such as collagen synthesis, bone resorption, cytokine production, or turnover of other matrix molecules, is often preferred.…”

What Is the Utility of Biomarkers for Assessing the Pathophysiology of Hip Osteoarthritis? A Systematic Review

“…Control [1,5,12,18,19,49]; atrophic versus hypertrophic in two studies [13,14]; and radiographic OA classification in five studies [6,23,42,47,48]. Two studies [15,20] analyzed minimum joint space width as a continuous variable relative to biomarker levels.…”

“…Urinary CTX-II and serum CRP levels were the only biomarkers with associations demonstrated in more than one study. Elevations in biomarker levels were noted with increasing severity of disease for uCTX-II in two studies [18,20] with an effect size (d) of 0.8 in one study [18]. Serum CRP levels were greater with more severe hip OA (1.3-2.9 times greater, effect size d = 1.2-1.8) than those with less severe OA.…”

Biomarkers and Ultrasound in the Knee Osteoarthrosis Diagnosis

“…Their concentration can be www.intechopen.com measured by immunoassay methods (Garnero et al,2006). Measuring the concentration of these biomarkers may be complementary with imaging techniques following up the development of diseases such as rheumatoid arthritis and osteoarthrosis (Garnero et al,2000).…”